IDEXX Laboratories, Inc. $IDXX Stock Position Raised by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC boosted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 15,184 shares of the company’s stock after purchasing an additional 994 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in IDEXX Laboratories were worth $9,703,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Blalock Williams LLC acquired a new position in shares of IDEXX Laboratories during the 3rd quarter worth $590,000. Arkadios Wealth Advisors bought a new stake in IDEXX Laboratories in the second quarter worth $405,000. Orion Porfolio Solutions LLC boosted its holdings in IDEXX Laboratories by 116.6% in the second quarter. Orion Porfolio Solutions LLC now owns 10,718 shares of the company’s stock worth $5,749,000 after purchasing an additional 5,770 shares in the last quarter. USA Financial Formulas acquired a new position in IDEXX Laboratories during the third quarter worth $2,381,000. Finally, Beacon Investment Advisory Services Inc. raised its holdings in IDEXX Laboratories by 15.7% during the third quarter. Beacon Investment Advisory Services Inc. now owns 56,241 shares of the company’s stock valued at $35,932,000 after buying an additional 7,616 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

IDXX opened at $697.82 on Tuesday. The stock’s 50 day simple moving average is $706.41 and its 200-day simple moving average is $657.44. The company has a current ratio of 1.18, a quick ratio of 0.87 and a debt-to-equity ratio of 0.24. The stock has a market cap of $55.72 billion, a PE ratio of 55.34, a P/E/G ratio of 3.71 and a beta of 1.67. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Monday, November 3rd. The company reported $3.22 EPS for the quarter, topping the consensus estimate of $3.14 by $0.08. The firm had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.IDEXX Laboratories’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same period last year, the business earned $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insider Transactions at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 9,425 shares of the company’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the sale, the executive vice president owned 21,149 shares of the company’s stock, valued at approximately $14,874,937.66. This represents a 30.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.98% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. JPMorgan Chase & Co. increased their price objective on IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a report on Tuesday, November 4th. BTIG Research upped their target price on IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Jefferies Financial Group reissued a “buy” rating and issued a $830.00 price target on shares of IDEXX Laboratories in a research report on Tuesday, November 4th. UBS Group upped their price target on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a report on Tuesday, November 4th. Finally, Leerink Partners set a $785.00 target price on IDEXX Laboratories in a report on Monday, November 3rd. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $763.50.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.